The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery

Perfusion. 1996 Jan;11(1):53-6. doi: 10.1177/026765919601100107.

Abstract

The effect of low-dose epsilon-aminocaproic acid (EACA) on the postoperative course of 46 patients was studied. Patients undergoing coronary artery bypass grafting were randomly selected in two groups. Group 1 (20 patients) received 5 g EACA upon initiation of cardiopulmonary bypass (CPB). Group 2 (26 patients) received no antifibrinolytic drugs prior to CPB. Neither group received antifibrinolytic drugs after CPB. There was no significant difference between the two groups' blood usage on CPB: 0.65 units in Group 1 and 0.60 units in Group 2. After CPB, blood usage significantly differed: 2.2 +/- 1.7 (SD) units in Group 1 and 3.9 +/- 3.0 units in Group 2 (p = 0.033). Significant difference was also demonstrated in postoperative blood loss in the first 24 hours: 1610 +/- 531 ml in Group 1 versus 2025 +/- 804 ml in Group 2 (p = 0.043). Pre-CPB administration of low-dose EACA significantly decreases blood loss and blood usage in the postoperative period.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aminocaproic Acid / therapeutic use*
  • Antifibrinolytic Agents / therapeutic use*
  • Coronary Artery Bypass / adverse effects*
  • Female
  • Humans
  • Male
  • Postoperative Hemorrhage / drug therapy*
  • Retrospective Studies

Substances

  • Antifibrinolytic Agents
  • Aminocaproic Acid